VAXCYTE, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 30 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-09-09: Reporting owner Jodar Luis; Form 3; Security Stock Option (right to buy); Transaction Holding.
- 2026-09-04: Reporting owner Jodar Luis; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-09-01: Reporting owner Wassil Jim; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-08-05: Reporting owner Dhaliwal Harpreet S.; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
PCVX insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-09 holding as of filing | Jodar Luis Officer (Chief Medical Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $47.30 exercise price | 2026-09-09 | ||
| 2026-09-04 | Jodar Luis Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +88,254 88,254 owned after | $61.16 exercise price | $61.16 | 2026-09-09 |
| 2026-09-01 | Wassil Jim Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,250 66,648 owned after | $5.35 exercise price | $60.81 | 2026-09-02 |
| 2026-08-05 | Dhaliwal Harpreet S. Officer (Chief Technical Ops Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,000 28,000 owned after | $24.79 exercise price | $55.92 | 2026-08-05 |
| 2026-08-03 | Wassil Jim Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,250 68,898 owned after | $5.35 exercise price | $53.53 | 2026-08-05 |
| 2026-08-03 | GUGGENHIME ANDREW Officer (PRESIDENT AND CFO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 216,827 owned after | $5.35 exercise price | $53.53 | 2026-08-05 |
| 2026-07-27 | PICKERING GRANT Director, Officer (CHIEF EXECUTIVE OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,198 137,000 owned after | $2.03 exercise price | $55.50 | 2026-07-28 |
| 2026-07-16 | Markels John Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,029 23,029 owned after | $56.04 exercise price | $56.04 | 2026-07-16 |
| 2026-07-06 | GUGGENHIME ANDREW Officer (PRESIDENT AND CFO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 226,827 owned after | $5.35 exercise price | $56.96 | 2026-07-06 |
| 2026-07-01 | Wassil Jim Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −516 71,148 owned after | $5.35 exercise price | $56.08 | 2026-07-06 |
| 2026-06-22 | Slaoui Moncef Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,061 26,061 owned after | $52.11 exercise price | $52.11 | 2026-06-23 |
| 2026-06-18 | PICKERING GRANT Director, Officer (CHIEF EXECUTIVE OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −225 0 owned after | $1.79 exercise price | $51.44 | 2026-06-18 |
| 2026-06-18 | GUGGENHIME ANDREW Officer (PRESIDENT AND CFO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 236,827 owned after | $5.35 exercise price | $51.44 | 2026-06-18 |
| 2026-06-15 | Paya Carlos V Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | BRANDICOURT OLIVIER Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,034 11,034 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Furey John Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Lee Jacks Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Gilbert Halley E Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Loxam Teri Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Drapeau Anne S Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-06-15 | Lukatch Heath Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,389 11,389 owned after | $49.56 exercise price | $49.56 | 2026-06-16 |
| 2026-04-07 | Cowan Elvia Officer (SVP, Finance & CAO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 93,068 owned after | $25.92 exercise price | $60.69 | 2026-04-08 |
| 2026-03-11 | Cowan Elvia Officer (SVP, Finance & CAO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 96,068 owned after | $25.92 exercise price | $57.53 | 2026-03-11 |
| 2026-02-26 | Cowan Elvia Officer (SVP, Finance & CAO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,855 17,855 owned after | $60.00 exercise price | $60.00 | 2026-03-02 |
| 2026-02-26 | Cowan Elvia Officer (SVP, Finance & CAO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,716 98,568 owned after | $25.92 exercise price | $60.00 | 2026-03-02 |
| 2026-02-26 | GUGGENHIME ANDREW Officer (PRESIDENT AND CFO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +74,993 74,993 owned after | $60.00 exercise price | $60.00 | 2026-03-02 |
| 2026-02-26 | PICKERING GRANT Director, Officer (CHIEF EXECUTIVE OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,698 175,698 owned after | $60.00 exercise price | $60.00 | 2026-03-02 |
| 2026-02-26 | Dhaliwal Harpreet S. Officer (Chief Technical Ops Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,424 46,424 owned after | $60.00 exercise price | $60.00 | 2026-03-02 |
| 2026-02-26 | Wassil Jim Officer (CHIEF OPERATING OFFICER) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +53,566 53,566 owned after | $60.00 exercise price | $60.00 | 2026-03-02 |
| 2026-01-15 | BRANDICOURT OLIVIER Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,750 6,750 owned after | $48.04 exercise price | $48.04 | 2026-01-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |